Exact Sciences Corporation (NASDAQ:EXAS) shares are trading higher Wednesday, and the stock has gained over 8% in the past month. Here’s a look at the latest Exact Sciences news:
What To Know:
Guggenheim analyst Subbu Nambi initiated coverage on Exact Sciences with a Buy rating and announced a price target of $90, and Wolfe Research analyst Doug Schenkel initiated coverage on Exact Sciences with an Outperform rating last week.
Exact Sciences presented new data and study results from its oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium on Dec. 7.
Dr. Rick Baehner, CMO of Precision Oncolog at Exact Sciences, said, “Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world’s most prestigious, breast cancer-focused organizations.”
Exact Sciences shares are moving on above-average trading volume Wednesday with more than 1.33 million shares already traded in the session. According to data from Benzinga Pro, the stock’s 100-day average volume is 1.565 million shares and the 50-day moving average is $64.54
EXAS Price Action: According to Benzinga Pro, Exact Sciences shares are up by 4.2% at $72.33 at the time of publication.
Image: Pete Linforth from Pixabay
